Lou Tartaglia, Ph.D.

Managing Partner atCure VenturesMassachusetts

Lou Tartaglia is a Managing Partner and Co-Founder of Cure Ventures. He has held leadership and investment roles across various biotech startups and venture capital firms.

What Lou can write

Writes checks ofNot reported
Comes in atPre-seed, Seed, Series A, Series BCan lead the round
Email the firm[email protected]The firm's own inbox for founders.

Career

  1. Third Rock Ventures · Partner
    2007-2014
  2. Editas · Chief Scientific Officer
  3. Rhythm · Chief Scientific Officer
  4. Agios · Chief Scientific Officer
  5. 4:59 · Head of
    2016
  6. Entrada Therapeutics · interim CEO
  7. 5AM Venture · Partner
  8. Cure Ventures · Managing Partner
    Now

Companies founded

Cure Ventures

Investments named in public bios

Entrada TherapeuticsEditasRhythmAgios

Focus

biotechventure capitaldrug discovery

Education

State University of New York at Albany, B.S. in ChemistryUniversity of California, Berkeley, Ph.D. in Biochemistry

Also at Cure Ventures

Partners like Lou

At firms with a similar stage, sector and check size.

Alert me when Cure Ventures is active

One email when Lou's firm raises a fund, adds a partner or shows new activity.

Founders and investors at a Mode VC gathering

Send Mode VC your deck

Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.

Send your deck

Questions

Who is Lou Tartaglia, Ph.D.?

Lou Tartaglia is a Managing Partner and Co-Founder of Cure Ventures. He has held leadership and investment roles across various biotech startups and venture capital firms.

How much does Lou Tartaglia, Ph.D. invest?

Cure Ventures has not reported a check size. It invests at pre-seed, seed, series a, series b.

How do I pitch Lou Tartaglia, Ph.D.?

Email [email protected], the firm's inbox for founders, and name Lou in the subject. A warm intro from a founder Cure Ventures backed works better.

What did Lou Tartaglia, Ph.D. do before Cure Ventures?

Partner at Third Rock Ventures; Chief Scientific Officer at Editas; Chief Scientific Officer at Rhythm; Chief Scientific Officer at Agios; Head of at 4:59; interim CEO at Entrada Therapeutics; Partner at 5AM Venture.

Last updated 2026-10-15. Is this you? Ask for a correction.